CD80 (B7-1)
B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1.
Overview
CD80 (chromosome 3q13.33), also called B7-1, is an immunoglobulin-superfamily costimulatory ligand that acts as the primary auxiliary signal for naive T cells by binding CD28, activating NF-kappa-B and MAPK and raising cytokine production and, through PI3K/AKT, T-cell glucose metabolism; it also binds CTLA-4, a decoy receptor that blocks CD28-mediated priming, and regulates PD-L1/PD-1 interactions (UniProt P33681). In OnCo it appears in the mechanism of the PD-L1 antibodies adebrelimab and sugemalimab, which block PD-L1 binding to PD-1 and to B7-1, and in the mechanism of ipilimumab, which stops CTLA-4 from outcompeting CD28 for B7 ligands during priming.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1.
- 1 · What it is
B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1.
- 2 · What goes wrong in cancer
The same ligand serves an accelerator (CD28) and a brake (CTLA-4), which is why CTLA-4 blockade increases T-cell priming. PD-L1 antibodies that also free B7-1 restore CD28 costimulation as well as lifting the PD-1 brake.
- 3 · How drugs use it
No product in this corpus aims at CD80 (B7-1) yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
External identifiers
Biology
The same ligand serves an accelerator (CD28) and a brake (CTLA-4), which is why CTLA-4 blockade increases T-cell priming. PD-L1 antibodies that also free B7-1 restore CD28 costimulation as well as lifting the PD-1 brake.
- Dendritic cells, macrophages and activated B cells
- Small-cell lung cancer (adebrelimab) and NSCLC and peripheral T-cell lymphoma (sugemalimab) populations
Notes
top- Prevalence not recorded in this wave: HGNC and UniProt carry no positivity rates and no other source was consulted.
Latest papers
topQuery for this target: (TITLE:"CD80" OR ABSTRACT:"CD80" OR TITLE:"B7-1" OR ABSTRACT:"B7-1" OR TITLE:"B7.1" OR ABSTRACT:"B7.1" OR TITLE:"CD28LG" OR ABSTRACT:"CD28LG" OR TITLE:"CD80 molecule" OR ABSTRACT:"CD80 molecule") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD80 (B7-1), not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCD137 (4-1BB, TNFRSF9)
Shares CD28, The cancer-immunity cycle, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1 and the tag wave5-target.
- TargetIDO1
Shares The cancer-immunity cycle, PD-L1, Immune checkpoint inhibitors and the tag wave5-target.
- TargetSHP2 (PTPN11)
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, Non-small-cell lung cancer and the tag wave5-target.
- TargetB7-H4 (VTCN1)
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation and the tag wave5-target.
- TargetHLA-A
Shares The cancer-immunity cycle and the tag wave5-target.
- TargetJAK1
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag wave5-target.
- TargetTET2
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag wave5-target.
- TargetFAK (PTK2)
Shares Non-small-cell lung cancer and the tag wave5-target.